期刊名称：CURRENT CANCER DRUG TARGETS
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Aims & Scope
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
Current Cancer Drug Targets publishes original research articles and a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
Indexed in
Chemical Abstracts, EMBASE, BIOBASE, MEDLINE, BIOSIS, Science Citation Index Expanded, ISI Web of Science, Biochemistry & Biophysics Citation Index?/FONT>, Biotechnology Citation Index?/FONT>, ISI Alerting Services, Index to Scientific Reviews, PubsHub ,BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Journal Citation Reports/Science Edition
Instructions to Authors
Instructions for Authors
Manuscripts should be submitted openly to the Editor-in-Chief without prior invitation at the following address: Dr. John K. Buolamwini, Editor-in-Chief, Current Cancer Drug Targets, Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, 847 Monroe Avenue, Suite 327, Memphis, TN 38163, USA, Phone: +1 901-448-7533, Fax: +1 901-448-6828, E-Mail: jbuolamwini@utmem.edu
Manuscript Preparation: Manuscripts may be submitted either in print or electronic format (preferable). For print submissions, the manuscript should be typed in double spacing throughout on A-4 or US Letter (8.5x11 inches) paper. Dot matrix print or any print that is difficult to read is unacceptable. Two copies of the manuscript must accompany the original (along with a computer disk) and should be sent to the Editor at his address. All pages should be numbered. For electronic submissions please refer to the instructions below on “Online Manuscript Submission".
Regular Reviews and Mini-Reviews: For 'Regular Review' articles, the manuscript, written in English, should not exceed 70 pages (ca. 30 printed pages) and for 'Mini-Reviews' a maximum of 30 manuscript pages in length (ca. 10 printed pages). 'Mini-reviews' can deal with an emerging area within cancer target research and 'Regular Review' articles can cover up to two areas of cancer target research.
Original Research Articles: The journal considers the publication of 'Original Research Papers', which represent scientifically rigorous novel research that addresses cancer target research, from biochemical, genetic, pharmacological and molecular levels using both cellular and in vivo systems. The journal also welcomes recent research work in fast emerging areas of cancer targets.
Single Topic (Thematic) Issues: These issues will be restricted to invited review articles. A Single Topic Special Editor will offer a short Perspective and co-ordinate the solicitation of between 6 to 10 manuscripts from leading scientists. Authors interested in editing a single topic issue in an emerging area in cancer research may submit their proposal to the Editor-in-Chief for his consideration.
Manuscript Organization: The manuscript should be divided as: Title page, abstract and the main text. The text may be subdivided further according to the areas to be discussed. This should be followed by the Acknowledgement (if any) and Reference sections. The first page should contain the title, the authors?names (initials and surname only), with an asterisk to mark the name of the principal author.
Conflict of Interest: Financial contributions to the work being reported should be clearly acknowledged, as should any potential conflict of interest.
Abstract: The abstract should not exceed 250 words and it should condense the essential features of the review article, with the focus on the major advances in the field.
Key Words: Authors must supply up to eight key words along with their manuscript.
Text: The main text should begin on a separate page and should be subdivided into separate sections. For research article, the preparation of the main text must be structured into separate sections as Introduction, Materials and Methods, Results, Discussion, and Conclusion. The review or mini-review article should give an introduction mentioning any previous important reviews in the field and contain a comprehensive discussion starting with the general background of the field. It should then go on to discuss the salient features of recent developments with a final conclusion at the end. The authors should avoid presenting material, which has already been published in previous review. The reference numbers should be given in square brackets in the text. Abbreviations should be defined the first time that they are used in the manuscript and a list of abbreviations used should also be provided. Acknowledgments should be kept to a minimum.
Tables:
- Data Tables should be submitted in Microsoft Excel or in Microsoft Word table format.
- Each table should include a title/caption explaining what the table shows. Detailed legends may then follow.
- Tables should be given on separate pages with indications on the left hand margin to the text, as to the appropriate placement of the tables.
- Tables should not contain vertical rules.
- Columns and rows of data should be made visibly distinct by ensuring the borders of each cell display as black lines.
- Tables should be numbered consecutively in order of their citation in the body of the text, with Arabic numerals.
- If a reference is cited in both the table and text, insert a lettered footnote in the table to refer to the numbered reference in the text.
- Tabular data provided as additional files can be submitted as an Excel spreadsheet.
Figures / Illustrations:
All authors must strictly follow the guidelines below for preparing illustrations for publication in Current Cancer Drug Targets.
Editorial Requirements:
The quality of the illustrations printed in the journal largely depends on the quality of the figures/illustration provided by the author. In preparing artwork or graphics for publication, keep in mind the following points.
- Submit the original artwork or a photographic print of the original for publication.
- Do not submit photocopies. (Hardcopy submission requirement).
- Illustrations should be provided as separate files, not embedded in the text. (Hardcopy submission requirement).
- Remove all color from graphics except for those illustrations (Greyscale), which are intended to be printed in color.
- Good quality of hardcopy originals are a requirement.
- Figures should be referred to as “Fig. (1)? “Fig. (2)?etc. in the text with figure numbers in bold within round bracket.
- Revised manuscripts should contain a complete set of artwork and photographs.
Technical Details:
- Figures should be provided on high quality, white, smooth opaque paper. (Hardcopy requirement).
Format & Resolution:
- The following file formats can be accepted. (Preference in order of appearance): PDF, TIFF, JPEG, GIF.
- Illustrations must fit a single or double column format on the journal page, according to the following guideline below:
|
HEIGHT |
WIDTH |
|
SINGLE COLUMN |
24 cm (max) |
8.5 cm (max) |
|
DOUBLE COLUMN |
24 cm (max) |
18 cm (max) |
- Whenever possible, submit graphics that do not have to be reduced to fit the standard figure size.
- Use the best resolution available. (hardcopy submission requirement). For online submission the maximum resolution is 300 dpi.
- Avoid textures and shadings giving a three-dimensional effect to the illustration.
- Symbols and lettering in the illustration should be of similar size.
- Smaller lettering is used.
- Font: Times New Roman or Helvetica is preferable. Font size: 10pt (maximum).
- Line drawings should have clear and sharp lines and should be of uniform density. Moreover, lines should be continuous without any breaks.
- Do not use lines thinner than 1 point.
Color Figures / Illustrations:
Photographs:
Submit high-contrast prints that are of single- or double-column width so that they will not have to be reduced when printed. Negatives are not acceptable. However, in case of hardcopy submission, color illustrations and plates can be published from 35 mm color slides.
Chemical Structures: Chemical structures must be prepared according to the guidelines below.
Structures should be prepared using a suitable drawing program e.g. ChemDraw and provided as separate file, submitted both on disk and in printed formats.
Numbers in bold should identify all chemical structure. If a name is also used to describe the compound, the associated number in bold should be in parenthesis, e.g. “compound (1)?
Structure Drawing Preferences:
[As according to the ACS style sheet]
Drawing Settings:
Chain angle 120?/P>
Bond spacing 18% of width
Fixed length 14.4 pt (0.500cm, 0.2in)
Bold width 2.0 pt (0.071cm, 0.0278in)
Line width 0.6 pt (0.021cm, 0.0084in)
Margin width 1.6 pt (0.096cm)
Harsh spacing 2.5 pt (0.088cm, 0.0347in)
Text settings:
Font Times New Roman / Helvetica
Size 10pt
Under the Preference Choose:
Units points
Tolerances 3 pixels
Under Page Setup Use:
Paper US letter
Scale 100%
References: References: All references must be numbered in the text in square brackets, e.g. [4], or [7-10, 15], in the order of citation in the text. Example:
[1] Seymore, L. Novel Anti-Cancer Agents in Development: Exciting Prospects and New Challenges. Cancer Treat. Revs. 1999, 25, 301-312.
[2] Furfine, E. S.; Leban, J. J.; Landavazo, A.; Moomaw, J. F.; Casey, P. J. Protein Farnesyltransferase: Kinetics of Farnesyl Pyrophosphate Binding and Product Release. Biochemistry 1995, 34, 6857-6862.
[3] Boyd, M. R. In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval; Teicher, B. A., Ed.; Humana Press: Totowa, NJ, 1997, pp. 23-42.
[4] Boynton, A. L.; McKeehan, W. L.; Whitfield, J. F., Eds. Ions, Cell Proliferation and Cancer; Academic Press: New York, 1982.
Abstracts, unpublished data, meeting reports and personal communications (which can be only included if permission has been obtained) should not be given in the reference section but they may be mentioned in the text and details provided as footnotes. All authors of referenced papers must be cited and there must be no use of the short hand version of et al. when citing the authors.
Manuscript Submission: Two copies of the manuscript must accompany the original along with the soft copy of the manuscript on a computer floppy disk(s) in MS Word file format (or created in any other well-known word processing software) should be submitted. To achieve rapid publication authors are encouraged to e-mail or fax their submission to the appropriate editorial office (see above) at the same time that they mail the manuscript. For even faster publication, authors are encouraged to submit their entire manuscript via Bentham’s online submission service (see below). Authors must provide their full address, telephone and fax numbers with e-Mail address with all submissions.
For expedient and speedy reviewing of author's manuscripts, authors are strongly advised to include the PDF file of their manuscript on a floppy or zip disk, into the mailing material. At the same time the package is mailed, please also send by e-mail a copy of the PDF file of the manuscript to the editorial office.
Online Manuscript Submission: (preferable)
To facilitate speedy and cost-effective submission of abstracts and manuscripts, an online submission and tracking service via Internet is being offered. Once the Editor-in-Chief of the journal has accepted your abstract, we would prefer that you submit your full manuscript online via our online submission service available at www.bentham-mps.org
For online submission, please provide your complete manuscript in the form of a single zipped folder containing all the material (main text, figures/ illustrations, scanned photographs, tables, chemical structures drawn in ChemDraw) as separate files and a PDF version of the entire manuscript with all the figures/ illustrations / tables / chemical structures etc., embedded in the text exactly in the manner as they should appear in printing.
Authors are required to proofread the PDF version of their manuscript before submission. The article will be published exactly as received and the Publishers will not be responsible for any error occurring in the manuscript in this regard.
For online submission of manuscripts, these should be submitted via our online manuscript submission service available at www.bentham-mps.org or by FTP submission at www.bentham-ftp.org
You may, however, still submit your abstracts and manuscripts through conventional surface mail.
A successful electronic submission of a manuscript will be followed by a system-generated acknowledgement to the principal/corresponding author within 72 hours of the dispatch of the manuscript. Any queries therein should be addressed to mahmood@bentham.org and copied to Jalil@bentham.org
Page Charges: No page charges will be levied to authors.
Language Editing: Manuscripts submitted containing many English typographical errors will not be published. Authors from non-English language countries are advised to use the services of our professional language editing department prior to submitting their manuscript to the Journal. Please contact Bentham Publishing Services www.bentham.org/bps for a language editing quote at e-mail: bps@bentham.org stating the total number of words of the article to be edited.
Proofs: Authors are sent page proofs. To avoid delays in publication, proofs should be checked immediately for typographical errors and returned within 48 hours. Authors will be charged for excessive changes made at the page proof stage.
Reprints: Each first named author will receive by e-mail a free copy of their article as a PDF file. The PDF file is a watermarked version of the published article which is exclusively for the author's own use and may not be copied or distributed. Reprints may be ordered from the Publisher prior to publication of the article. First named authors may also order a personal print and online subscription of the journal at 50% off the normal subscription rate by contacting the subscription department at e-mail: subscriptions@bentham.org
Bentham Open Access: Accepted articles can be published online for an immediate free open access for all to view. Open access publishing provides the maximum dissemination of the article to the largest audience. Authors must pay for this service. For more information please contact us at e-mail: openaccess@bentham.org
Reviewing and Promptness of Publication: All papers submitted for publication will be immediately subjected to editorial scrutiny, usually in consultation with members of the Editorial Advisory Board. Every effort will be made to assess the papers quickly. The papers will be typeset and the proofs dispatched to the authors normally within 4 weeks of their acceptance.
Copyright: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.
Editorial Board
Editor-in-chief:
John K. Buolamwini
Department of Pharmaceutical Sciences
College of Pharmacy
University of Tennessee Health Science Center
847 Monroe Avenue, Suite 327
Memphis, TN 38163, USA
Tel: +1 901- 448-7533
Fax: +1 901- 448-6828
E-mail: JBuolamwini@utmem.edu
Associate Editors:
Alex A. Adjei
Mayo Clinic
Rochester, MN, USA
E-mail: adjei.alex@mayo.edu
Yoon Sang Cho-Chung
Laboratory of Tumor Immunology and Biology
National Cancer Institute
Bethesda, MD, USA
E-mail: chochung@helix.nih.gov
Nouri Neamati
University of Southern California
Los Angeles, CA, USA
E-mail: neamati@usc.edu
Herbert E. Nieburgs
Department of Pathology
University of Massachusetts
MA, USA
E-mail: editor@cancerprev.org
Francis Ali-Osman
Comprehensive Cancer Center
Duke University Medical Center
Durham, NC, USA
E-mail: alios001@mc.duke.edu
Silvio Parodi
National Institute for Research on Cancer
University of Genoa
Genoa, Italy
E-mail: silvioparodi@istge.it
Takashi Sugimura
National Cancer Center Research Institute
Tokyo, Japan
E-mail: tsugimur@gan2.ncc.go.jp
Paul Workman
Cancer Research Campaign Centre for Cancer Therapeutics
Institute for Cancer Research
Surrey, England
E-mail: p.workman@icr.ac.uk
Editorial Advisory Board:
Sarki A. Abdulkadir (Vanderbilt University Medical Center, Nashville, TN, USA)
Sudhir Agrawal (Idera Pharmaceuticals, Inc., Cambridge, MA, USA)
Joseph J. Barchi Jr. (National Cancer Institute, Frederick, MD, USA)
Terrence R. Burke Jr. (National Cancer Institute, Bethesda, MD, USA)
Michael P. Carty (National University of Ireland, Galway City, Ireland)
Carol E. Cass (University of Alberta, Edmonton, Alberta, Canada)
Zeger Debyser (Rega Institute for Medical Research, Leuven, Belgium)
William A. Denny (The University of Auckland, Auckland, New Zealand)
Manel Esteller (Spanish National Cancer Centre (CNIO), Madrid, Spain)
Lynn Ferguson (University of Auckland, Auckland, New Zealand)
Silvio De Flora (University of Genoa, Genoa, Italy)
Michelle Haber (University of New South Wales, Sydney, Australia)
Chuanshu Huang (New York University School of Medicine, NY, USA)
Nam-ho Huh (Okayama University Graduate School of Medicine, Okayama, Japan)
Johji Inazawa (Tokyo Medical and Dental University, Tokyo, Japan)
Hideki Kasuya (Nagoya University School of Medicine, Nagoya Aichi, Japan)
Evan T. Keller (University of Michigan, Ann Arbor, MI, USA)
Robert S. Kerbel (Sunnybrook & Women's College Health Sciences Centre, Toronto, Canada)
Marene Landström (Ludwig Institute for Cancer Research, Uppsala, Sweden)
Edision T. Liu (Genome Institute of Singapore, Singapore)
Ya-Qiu Long (Shanghai Institute of Materia Medica, Shanghai, China)
Sridhar Mani (Albert Comprehensive Cancer Center, Bronx, NY, USA)
David J. McC (MD Anderson Cancer Center, Houston, TX, USA)
Masato Mutoh (Toray Industries, Inc., Kamakura, Kanagawa, Japan)
Kyriacos C. Nicolaou (Scripps Research Institute, San Diego, CA, USA)
Assam El-Osta (Baker Medical Research Institute, Victoria, Australia)
Yuan-Ping Pang (Mayo Clinic Cancer Center, Rochester, MN, USA)
Yves Pommier (National Cancer Institute, Bethesda, MD, USA)
Garth Powis (Arizona Cancer Center, Tucson, AZ, USA)
Balazs Sarkadi (National Medical Center, Budapest, Hungary)
M.S. Sheikh (SUNY Upstate Medical University, Syracuse, NY, USA)
George S.W. Tsao (University of Hong Kong, Hong Kong, China)
Kristiina Vuori (The Burnham Institute, La Jolla, CA, USA)
John N. Weinstein (National Cancer Institute, Bethesda, MD, USA)
Daniel Zaharevitz (National Cancer Institute, Rockville, MD, USA)
Ruiwen Zhang (Univ. of Alabama at Birmingham, Birmingham, AL, USA)
|
